Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Invest Dermatol. 2021 Jun 3;141(12):2908–2920.e7. doi: 10.1016/j.jid.2021.04.023

Figure 6. Romidepsin combined with ruxolitinib treatment decreases tumor load in a mouse model of Sezary syndrome.

Figure 6.

(a) Quantitative analyses of changes in tumor burden measured by bioluminescence at the endpoint analysis. (b, c) Quantitative analyses of changes in tumor burden measured by bioluminescence at different time points represented as fold change (b) or total counts (c). P values were calculated using a two-tailed Student’s t-test. Error bars, mean ± s.d. *p ≤ 0.05.